Consistent with previously published data, we determined that the ATR inhibitor, AZD6738, and the PARP inhibitor, AZD2281, radiosensitised all prostate cancer cells to low LET (Figure 2 and Table 2) [32,33]. Here, ATR is linked to prostate carcinoma.